Related Experiment Video

Updated: Aug 22, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Benefits of SGLT2 inhibitors in arrhythmias

Jinghan Gao1, Genlong Xue1, Ge Zhan1

  • 1Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.

Frontiers in Cardiovascular Medicine
|November 7, 2022
PubMed

Insights

Sodium-glucose cotransporter (SGLT) 2 inhibitors show promise in reducing cardiovascular disease risk. This review explores how SGLT2 inhibitors mitigate arrhythmia by influencing electrical and structural remodeling.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Sodium-glucose cotransporter (SGLT) 2 inhibitors are recognized for cardiovascular benefits, including reducing heart failure (HF) and myocardial infarction.
  • Emerging evidence suggests SGLT2 inhibitors also play a role in reducing the risk of cardiac arrhythmias.

Purpose of the Study:

  • To explore the mechanisms by which SGLT2 inhibitors reduce arrhythmia risk.
  • To investigate the impact of SGLT2 inhibitors on electrical and structural remodeling in the context of arrhythmias.

Main Methods:

  • Review of existing literature on SGLT2 inhibitors and their effects on cardiac electrophysiology and structure.
  • Analysis of studies focusing on ion homeostasis (Na+, Ca2+) and its relation to SGLT2 inhibition.
  • Examination of the influence of SGLT2 inhibitors on fibrosis, inflammation, oxidative stress, and apoptosis in cardiac tissue.

Main Results:

  • SGLT2 inhibitors impact Na+ and Ca2+ homeostasis, influencing electrical remodeling and potentially preventing arrhythmias.
  • SGLT2 inhibitors demonstrate protective effects against structural remodeling by mitigating fibrosis, inflammation, oxidative stress, and apoptosis.
  • These mechanisms collectively contribute to the observed cardiovascular benefits of SGLT2 inhibitors.

Conclusions:

  • SGLT2 inhibitors offer significant benefits for cardiovascular diseases, including heart failure and myocardial infarction.
  • SGLT2 inhibitors are expected to reduce the risk of cardiac arrhythmias through modulation of electrical and structural remodeling.
  • Further research into these mechanisms can optimize the use of SGLT2 inhibitors for comprehensive cardiovascular protection.
Keywords:
SGLT2 inhibitorsarrhythmiaelectrical remodelingmechanismsstructural remodeling

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
232
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
819
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
266
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
237
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
224
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
680